

A biocatalytic approach for kinetic resolution toward enantiopure anti-cancer β -lactams using *Candida antarctica* Lipase B

Evan C. McLoughlin and Niamh M. O'Boyle

The School of Pharmacy and Pharmaceutical Sciences, Trinity College, The University of Dublin, Ireland

INTRODUCTION

The combretazet β -lactams are *cis*-restricted analogues of combretastatin A-4 (CA-4, **Figure 1**), chemically manipulated by insertion of the 2-azetidinone scaffold to enhance their *in vitro* and *in vivo* stability. 3-Hydroxyl combretazets (**Figure 1**) demonstrate excellent anti-proliferative IC_{50} values in sub nanomolar ranges across a panel of cancer cell lines. Their 3*S*,4*S* enantiomers/eutomers (**Figure 1**) have been isolated using chiral diastereomeric resolution using *N*-Boc-L-proline.^{1,2} This approach required large process mass intensities (PMI) of approximately 150,000 kg/kg and produced only modest yields (5-10%) of enantiomers, insufficient for progression toward *in vivo* pre-clinical toxicology studies. Chemoenzymatic kinetic resolution (KR) of enantiomers using lipase *Candida antarctica* lipase B (CAL-B) in comparison offers a sustainable, greener and safer resolution process.




Figure 1: Chemical structures of combretastatin A-4 and β -lactam enantiomers (3*S*,4*S* eutomers and 3*R*,4*R* distomers)

OPTIMISED KR PROCEDURE

Early experiments resulted in rapid methanolysis and conversion and demonstrated poor *ee*. The most optimal conditions were selected for enantioseparation of 3-hydroxyl 3*S*,4*S* eutomers and 3*R*,4*R* 3-acetoxy distomers (**Scheme 1**).

1. Reaction quenching *via* filtration at 30-50% conversion/methanolysis.

✓ Quenching <50 % \uparrow *ee* of 3*S*,4*S* enantiomers.


2. Reactions carried out using 3 eq of methanol and 1:2 ratio of CAL-B: racemate.

✓ Reducing methanol from 10 \rightarrow 3 eq \downarrow reaction rate.

✓ Reducing ratio of enzyme: substrate from 1:1 \rightarrow 1:2 \downarrow reaction rate.

✓ \downarrow reaction rate \uparrow *ee*.

3. Isolation of unreacted, enantioenriched 3-acetoxy substrate *via* LC purification followed by further enantioenrichment in a second KR.



CAZ-1a R¹ = H, R² = OCH₃
CAZ-2a R¹ = F, R² = OCH₃
CAZ-3a R¹ = CH₃, R² = OCH₃
CAZ-4a R¹ = Cl, R² = OCH₃
CAZ-5a R¹ = Br, R² = OCH₃
CAZ-6a R¹ = H, R² = OCH₃
CAZ-7a R¹ = NH₂, R² = OCH₃
CAZ-8a R¹ = H, R² = OCH₂OCH₃
CAZ-9a R¹ = H, R² = OCH₂OCH₃

CAZ-1b R¹ = H, R² = OCH₃
CAZ-2b R¹ = F, R² = OCH₃
CAZ-3b R¹ = CH₃, R² = OCH₃
CAZ-4b R¹ = Cl, R² = OCH₃
CAZ-5b R¹ = Br, R² = OCH₃
CAZ-6b R¹ = H, R² = OCH₃
CAZ-7b R¹ = NH₂, R² = OCH₃
CAZ-8b R¹ = H, R² = OCH₂OCH₃
CAZ-9b R¹ = H, R² = OCH₂OCH₃

Scheme 1: Kinetic resolution of chiral combretazet enantiomers using *Candida antarctica* lipase B and methanol in MTBE. Reactions were carried out under continuous stirring in Quick-Thread Glass Reaction Tube 24x150mm using Radley Carousel 12 Plus Reaction Station™.




Figure 2: XRD of 3*S*,4*S* CAZ-6b isolated *via* KR.

Table 3: Comparison of *ee* values obtained *via* chiral diastereomeric resolution versus KR. 3*R*,4*R* enantiomers isolated as 3-acetoxy derivatives and compared to *ee* values of the corresponding 3-hydroxyl enantiomers isolated *via* chiral diastereomeric resolution.

Compound	<i>Ee</i> (%) obtained <i>via</i> diastereomeric resolution	<i>Ee</i> (%) obtained <i>via</i> kinetic resolution
CAZ-1b (S,S)	94	74
CAZ-1a (R,R)	71	99
CAZ-2b (S,S)	78	86
CAZ-4b (S,S)	91	81
CAZ-4a (R,R)	78	99
CAZ-3b (S,S)	66	78
CAZ-3b (R,R)	50	68
CAZ-5b (S,S)	84	76
CAZ-5a (R,R)	85	96
CAZ-6a (S,S)	84	81
CAZ-6b (R,R)	85	98




Figure 3: % conversion and *ee* of 3*S*,4*S* CAZ-2a \rightarrow CAZ-2b during optimisation reactions (1:1 CAL-B: CAZ-2a and 10 eq of methanol) illustrating higher *ee* between 30-40 hours versus after 60 hours

Table 1: Optimised CAL-B mediated methanolysis of CAZ-1a - CAZ-8a for isolation of 3*S*,4*S* 3-hydroxyl eutomers in 62-86% *ee*

	Scale (mmol)	Time	conversion ¹	3 <i>R</i> ,4 <i>R</i> 3-acetoxy yield (s)	% <i>ee</i> _s	3 <i>S</i> ,4 <i>S</i> 3-hydroxyl yield (p)	% <i>ee</i> _p	E ²
CAZ-1a \rightarrow CAZ-1b	1	24 h	29%	37%	44	36%	82	16
CAZ-2a \rightarrow CAZ-2b	1	8 d	22%	29%	18	11%	86	16
CAZ-3a \rightarrow CAZ-3b	1	3 d	40%	54%	52	26%	70	9
CAZ-4a \rightarrow CAZ-4b	1	5 d	38%	36%	42	17%	81	14
CAZ-5a \rightarrow CAZ-5b	1	5 d	38%	36%	42	17%	81	8
CAZ-6a \rightarrow CAZ-6b	1	4 d	45%	31%	66	34%	76	14
CAZ-7a \rightarrow CAZ-7b	0.1	3 d	41%	11%	40	8%	62	6
CAZ-8a \rightarrow CAZ-8b	1	6 d	22%	29%	24	4.3%	62	9
CAZ-9a \rightarrow CAZ-9b	1	2 d	43%	34%	66	25%	70	12

¹measured using ¹H NMR at 400 MHz in CDCl₃, ²Enantiomeric ratio (calculated using ENANTIO online tool), ³substrate, ⁴product, Reactions were carried out under continuous stirring in Quick-Thread Glass Reaction Tube 24x150mm using Radley Carousel 12 Plus Reaction Station™.

Table 2: The second kinetic resolution of the double resolution strategy for isolation of 3-acetoxy 3*R*,4*R* enantiomers using CAL-B in \geq 98% *ee*.

Compound	<i>ee</i> prior to second KR (%)	Time	Conversion	3-acetoxy (s) yield	<i>ee</i> (%)
CAZ-1a	32	4 d	52%	30%	99
CAZ-4a	42	5 d	43%	36%	99
CAZ-5a	40	3.5 d	63%	16%	96
CAZ-6a	66	3.5 d	42%	20%	98
CAZ-9a	64	5 d	36%	16%	99

1:1 CAL-B: 3-acetoxy β -lactam, 6 eq of methanol, 0.5 mmol scale. Reactions were carried out under continuous stirring in Quick-Thread Glass Reaction Tube 24x150mm using Radley Carousel 12 Plus Reaction Station™.

Table 4: PMI of chiral resolution versus KR

Total mass required for synthesis	Chiral diastereomeric resolution				Kinetic resolution				
	Overall enantiomer yield % (mg)				Overall enantiomer yield % (mg)				
3753 - 4753 g	3 <i>S</i> ,4 <i>S</i> CAZ-1b	3 <i>R</i> ,4 <i>R</i> CAZ-1	3 <i>S</i> ,4 <i>S</i> CAZ-2b	3 <i>R</i> ,4 <i>R</i> CAZ-2	~ 700 mg	3 <i>S</i> ,4 <i>S</i> CAZ-1b	3 <i>R</i> ,4 <i>R</i> CAZ-1a	3 <i>S</i> ,4 <i>S</i> CAZ-2b	3 <i>R</i> ,4 <i>R</i> CAZ-2
	7 (25.2)	9 (32.4)	6 (23)	5 (19)		16-36 (30-130)	60 (30)	6-16 (6-30)	Nd
PMI (kg/kg)	148,810 - 188,492				PMI (kg/kg)	5-23	23	23-116	Nd
Fold reduction in PMI using KR versus chiral diastereomeric resolution (minimum)	3 <i>S</i> ,4 <i>S</i> CAZ-1b		3 <i>R</i> ,4 <i>R</i> CAZ-1a		3 <i>S</i> ,4 <i>S</i> CAZ-2b		3 <i>R</i> ,4 <i>R</i> CAZ-2		
	6470		6470		1010		Nd		

CONCLUSIONS

- Isolation of a panel of β -lactam enantiomers in excellent *ee* using a sustainable biocatalytic approach with lipase enzyme CAL-B has been achieved.
- Ring opening reactions of 3-acetoxy β -lactams have not been observed underpinning chemical stability of β -lactam ring, of relevance for formulation strategies.
- Reduction >6000 fold in PMI using KR versus diastereomeric resolution. KR is a sustainable and greener alternative to chiral diastereomeric resolution.
- Cost effective and reduces requirement for skilled labour.
- Rapid and accessible process proposed for scale up and commercial development of novel anti-cancer combretazet APIs for the treatment of triple negative breast and chemo-resistant colorectal cancers.

ACKNOWLEDGEMENTS

We would like to thank the Royal Society of Chemistry Research Enablement Grant (E22-0457725696) for funding this research.

REFERENCES

- McLoughlin, E. C.; O'Brien, J. E.; Trujillo, C.; Meegan, M. J.; O'Boyle, N. M., Application of 2D EXSY and qNMR Spectroscopy for Diastereomeric Excess Determination Following Chiral Resolution of β -Lactams. *ChemistryOpen* 2022.
- McLoughlin, E. C.; Twamley, B.; O'Brien, J. E.; Hannon Barroeta, P.; Zisterer, D. M.; Meegan, M. J.; O'Boyle, N. M., Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl β -lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers. *Bioorg Chem* 2023, 141, 106877.



The 9th International Electronic Conference on Medicinal Chemistry

01-30 November 2023 | Online

